Abstract
Selective cyclo-oxygenase (COX)-2 inhibitors have been proposed as potentially useful agents in the chemoprevention of nonmelanoma skin cancer (NMSC).1 Although COX-2 inhibitors are not without considerable risks, they may hold benefit for certain patient subgroups at risk for NMSC. In this article, we review studies examining the use of these agents in cancer prevention,2-7 and offer suggestions for future investigations with oral and topical COX-2 inhibitors in the prevention of NMSC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
